This ADC product is comprised of an anti-C. diff toxin B monoclonal antibody conjugated via a MC-Vc linker to MMAE. The MMAE is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAE binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
ADC Target
- Alternative Names
- C. diff toxin B, Clostridium difficile Toxin B
- Overview
- Clostridium difficile Toxin B (tcdB or ToxB) is a glucosyltranferase which is known to innactivate Rho, Cdc42 and Rac within target cells. This toxin is encoded on a pathogenicity region of the C. difficile chromossome and is expressed during the log and stationary phases of growth in response to a variety of environmental stimuli.
ADC Antibody
- Overview
- Human Anti-C. diff toxin B IgG1-kappa antibody, Bezlotoxumab
- Generic name
- Bezlotoxumab
ADC Linker
- Name
- MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl)
- Description
- Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
ADC payload drug
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products